This article is more than 5 years old. Information may no longer be current.
World Congress of Dermatology highlights: Psoriasis, atopic dermatitis
Patients with moderate to severe psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study data presented at the World Congress of Dermatology in Milan.
In other research from the meeting, scalp psoriasis clearance was achieved with mirikizumab and two phase 3 atopic dermatitis studies are highlighted below.
Ixekizumab yields ‘durable response’ in psoriasis clearance at 5 years
“Our results may convince some [clinicians] using agents that do not demonstrate this durable response to reconsider how they treat patients. For those familiar with biologics, or even ixekizumab, this reinforces the confidence that they have in the product,” Kim A. Papp, MD, PhD, FRCPC, a clinical investigator in the study, told Healio Dermatology. Read more.
Patients maintain scalp psoriasis clearance with higher doses of mirikizumab
Clearance of scalp psoriasis was maintained at 52 weeks with higher doses of mirikizumab, a humanized monoclonal antibody, according to study data. Read more.
Baricit i nib improves atopic dermatitis signs, symptoms at 16 weeks
Baricitinib significantly improved the signs and symptoms of moderate to severe atopic dermatitis compared with placebo, according to results from two phase 3 studies, BREEZE-AD1 and BREEZE-AD2. Read more.